Plain-English translation of NCT03676504 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called RV-SFG.CD19.CD28.4-1BBzeta CAR T cell therapy for patients with certain blood cancers—including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and several types of lymphoma—that have stopped responding to standard chemotherapy or come back after treatment. The approach works by taking your own immune cells, training them in the laboratory to recognize and attack cancer cells, and then putting them back into your body. This is a Phase 1/2 study, meaning it's designed to learn whether this medication is safe and how well it works.
Many patients with advanced blood cancers run out of effective treatment options when their cancer becomes resistant to standard chemotherapy or returns after treatment. This trial exists to find out whether this new cell-based approach—which uses a patient's own immune system as a personalized weapon—could offer hope to people in that situation.
You likely qualify if…
You likely don't qualify if…
You would first undergo chemotherapy ( and ) to prepare your body, followed by a procedure to collect your immune cells. Your cells would be sent to the laboratory to be modified and grown, a process that takes several weeks. Once ready, you would receive the modified cells back through an infusion. You would then need close monitoring in the hospital and at follow-up visits to watch for how your body responds and to manage any side effects. The study will follow you for a period of time to understand whether this treatment works for your cancer and how safe it is.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Germany